Join
Live feed
·
INSIDERFilingvia Quantisnow
MoonLake Immunotherapeutics logo

Chief Financial Officer Bodenstedt Matthias sold $862,205 worth of Class A ordinary shares (39,120 units at $22.04) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,115,435 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
MLTX· MoonLake Immunotherapeutics
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MLTX (MoonLake Immunotherapeutics) and more on Quantisnow.